SG Americas Securities LLC Has $1.14 Million Holdings in ICU Medical, Inc. $ICUI

Posted by Geri Gentry on Jul 5th, 2026

SG Americas Securities LLC raised its holdings in shares of ICU Medical, Inc. (NASDAQ:ICUI – Free Report) by 117.3% during the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 8,832 shares of the medical instruments supplier’s stock after acquiring an additional 4,767 shares during the quarter. SG Americas Securities LLC’s holdings in ICU Medical were worth $1,141,000 at the end of the most recent quarter.

A number of other large investors also recently made changes to their positions in the business. Millennium Management LLC lifted its position in shares of ICU Medical by 173.4% in the third quarter. Millennium Management LLC now owns 1,089,017 shares of the medical instruments supplier’s stock worth $130,638,000 after purchasing an additional 690,694 shares in the last quarter. Norges Bank purchased a new position in ICU Medical during the fourth quarter valued at approximately $58,083,000. Thrivent Financial for Lutherans grew its position in ICU Medical by 1,604.0% during the fourth quarter. Thrivent Financial for Lutherans now owns 303,457 shares of the medical instruments supplier’s stock valued at $43,294,000 after purchasing an additional 285,648 shares in the last quarter. UBS Group AG increased its stake in ICU Medical by 239.8% in the 3rd quarter. UBS Group AG now owns 386,555 shares of the medical instruments supplier’s stock valued at $46,371,000 after buying an additional 272,782 shares during the period. Finally, Brown Advisory Inc. acquired a new position in ICU Medical in the 4th quarter valued at approximately $32,445,000. Institutional investors and hedge funds own 96.10% of the company’s stock.

ICU Medical Price Performance

Shares of ICUI opened at $154.97 on Friday. The firm has a market cap of $3.87 billion, a PE ratio of 83.77, a PEG ratio of 2.17 and a beta of 0.76. The firm’s 50 day moving average price is $133.71 and its 200 day moving average price is $138.59. The company has a debt-to-equity ratio of 0.60, a quick ratio of 1.17 and a current ratio of 2.34. ICU Medical, Inc. has a twelve month low of $107.00 and a twelve month high of $160.29.

ICU Medical (NASDAQ:ICUI – Get Free Report) last posted its earnings results on Thursday, May 7th. The medical instruments supplier reported $1.97 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.78 by $0.19. The firm had revenue of $525.77 million during the quarter, compared to analysts’ expectations of $520.65 million. ICU Medical had a net margin of 2.15% and a return on equity of 7.50%. The company’s revenue was down 12.3% compared to the same quarter last year. During the same period in the previous year, the company earned $1.72 earnings per share. ICU Medical has set its FY 2026 guidance at 7.750-8.450 EPS. As a group, research analysts expect that ICU Medical, Inc. will post 6.5 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities research analysts have issued reports on the stock. Wall Street Zen upgraded shares of ICU Medical from a “hold” rating to a “buy” rating in a research report on Saturday, May 9th. Piper Sandler dropped their price target on shares of ICU Medical from $178.00 to $163.00 and set an “overweight” rating on the stock in a research note on Friday, April 17th. Zacks Research upgraded ICU Medical from a “hold” rating to a “strong-buy” rating in a report on Monday, June 29th. KeyCorp cut their price objective on ICU Medical from $180.00 to $164.00 and set an “overweight” rating for the company in a report on Monday, April 27th. Finally, Sanford C. Bernstein cut ICU Medical to a “market perform” rating in a research report on Monday, June 15th. Three analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Buy” and a consensus price target of $168.40.

Check Out Our Latest Research Report on ICU Medical

Insiders Place Their Bets

In related news, Director David C. Greenberg sold 2,424 shares of ICU Medical stock in a transaction on Tuesday, May 12th. The shares were sold at an average price of $122.91, for a total value of $297,933.84. Following the completion of the sale, the director owned 7,960 shares of the company’s stock, valued at approximately $978,363.60. The trade was a 23.34% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, VP Virginia Ruth Sanzone sold 2,447 shares of the company’s stock in a transaction on Thursday, May 14th. The stock was sold at an average price of $124.08, for a total transaction of $303,623.76. Following the completion of the sale, the vice president owned 19,460 shares of the company’s stock, valued at $2,414,596.80. This represents a 11.17% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. 2.10% of the stock is currently owned by company insiders.

About ICU Medical

(Free Report)

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.